With the P1a dosing regime and focus on safety, and not optimal dosing it has me questioning how much cpacs/mopacs data we will get. There is no doubt Bis is an anti cancer drug. This will not move the dial. Sorry should've worded my Q better- Do we have to wait until P1b to get the juice that will awaken the market via CPAcs in human validation?
Thank you @Dprent
No e the less. Dosing someone end of June is not good enough
Ann: March 2025 Quarterly Activity Report and Appendix 4C, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.015(1.27%) |
Mkt cap ! $208.4M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.20 | $1.17 | $139.7K | 118.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 666 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 7691 | 3 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |